This is how SVFC will make money! And it is already generating royalities : )
Technology Licensing
IntelliCell will license its suite of technology and protocol to physicians
or surgery centers for use among their patients.
ICBS Lab Technician runs the process ensuring quality control and GMP &
GLP compliance.
OP PORTUNI T Y HIGHL IGHT S
?? Orthopedics: Over 1 Million Hip and knee replacements, 600,000
back procedures performed annually in the U.S. where SVFs could
potentially mitigate the need for surgery.
?? Sports Medicine: A $1.3B addressable market and a key corporate
focus with meaningful partnerships already secured.
?? Periodontal Disease: A $6B addressable market; IntelliCell has
recently completed case studies using SVFs in the treatment of gum
recession showing no need for grafting
SPORTS MEDICINE
Sports Medicine is a key strategic focus for IntelliCell
as it seeks to build broad brand awareness among
both professional and non-professional athletes.
?? IntelliCell’s efforts led by Dr. James Andrews of the
Andrews Sports Medicine and Orthopedic Centers.
?? Planned multi-center clinical study exploring SVF’s
impact on osteoarthritis of the knee.
MARKET OPPORTUNITY
?? 17,000 Professional Athletes in the U.S.
?? 50,000 NCAA Division I Athletes in the U.S.
???? Millions of amateur athletes and aging boomers
REVENUE MODEL FOR LICENSING
?? $150,000 in upfront licensing fees for
equipment, installation, and training.
?? Yields high margin revenues for IntelliCell.
?? $1,000 in per procedure fees to IntelliCell.
?? Two procedures per week per lab
generates $100,000 in annual revenues
for IntelliCell.
?? IntelliCell estimates 100 labs will be
operational by year-end 2013.
Licensing Partners: Territories
IntelliCell has licensed its Technology to International partners for large
upfront payments and ongoing royalties.
SECURED PARTNERS
?? Licensed by RegenaStem in Canada (operating as IntelliCell
BioSciences of Canada) for $500,000 upfront and a 30% share of
revenues.
?? Licensed by Cell-Innovations, Pty Limited in Australia for $700,000
upfront and a 12.5% share of revenues.
PROSPECTIVE PARTNERS
?? Middle East led by Saudi Arabia
?? Thailand
?? Malaysia
?? Indonesia
ACTIVE PARTNERSHIP DISCUSSIONS
?? Wound Care: The Global wound care market generated $6.2B in 2010.
Over the course of the next decade, demand for advanced wound care will
increase due to an increasing prevalence of chronic wounds as diabetes and
obesity rates increase.
?? Heart Disease: Cytori, an IntelliCell peer that harvests stem cells from
adipose tissue using enzymes, is sponsoring three European clinical trials to
evaluate the use of adipose-derived stem and regenerative cells in the
treatment of acute myocardial infarction and chronic myocardial ischemia
and recently received FDA approval for IDE.
?? Adipose stem cell heart attack trial data published in the Journal of
American College of Cardiology in January 2012.
?? IntelliCell is in discussion with several partners who may desire a
substantially similar solution that leverages IntelliCell technology.
Centers of Excellence
Centers of Excellence are IntelliCell
managed locations where patients can
receive SVF treatments.
?? First Center to open in April 2012 offering
cosmetic and dermatologic procedures.
?? Centers of Excellence receives $10,000 per
patient per procedure versus $1,000 in the lab
sales model.
?? Centers of Excellence receives $2,500 per
procedure when other physicians utilize the
facility.
PLANNED CENTERS
?? Beverly Hills, CA
?? Miami, FL
?? Houston, TX
SVF Cryo-Storage
IntelliCell’s Cryo-Storage Service will create a large stream of highmargin
recurring revenues.
?? $500 for initial collection.
?? $200 per dose per year for storage.
?? $1,000 for removal from storage and shipment to physicians for use
by patient.
OPPORTUNITY
?? 500,000 liposuction procedures performed annually, an ideal source
of customers who have ready access to adipose tissue.
?? Examining acquisitions and joint ventures opportunities with several
prominent cryo-storage companies.
